Search Resources
Search Resources

Updated Resources

0 July 27, 2015

We’ve updated the resources for pharmacists by including a page with a list of training and CE opportunities for pharmacists. You can access the list here: http://rxpgx.com/resources/pharmacist-resources-2/training-opportunities This new resources will be updated as more CE opportunities are made available.

Posted in Uncategorized by Rachel Mills
0 June 19, 2015

We’ve updated the resource that includes a table of all medications with pharmacogenetic information in their drug label. All updates were made based on changes to a similar table maintained by the FDA. Changes include the additional of links to new CPIC guidelines for Celexa®(citalopram), Luvox® CR(fluvoxamine), Paxil®(paroxetine), Dilantin®(phenytoin), Elitek®(rasburicase), and Incivek®(telaprevir). See the entire table under the “Pharmacist Resources” tab or by clicking here.

Posted in Uncategorized by Rachel Mills
0 May 21, 2015

On May 5, 2015 the Duke Clinical Research Institute (DCRI) sponsored a lecture on Pharmacogenetics in Cardiovascular Disease. View the video here, or via the DCRI YouTube page where you can view other past lectures.

Posted in Uncategorized by Rachel Mills
0 May 19, 2015

A new clinical pharmacogenetics implementation consortium (CPIC) review and guideline have been published regarding pharmacogenetic testing and prescribing of the immunosuppressant drug tacrolimus. Published literature leading to this guideline has shown that extensive and intermediate CYP3A5 metabolizers have decreased concentrations of tacrolimus, suggesting that the starting dose should be increased 1.5 to 2 times the recommended dose. Therapeutic drug monitoring is also recommended to further guide dose adjustments. The review and guidelines can be viewed online via PharmGKB  or in the journal Clinical Pharmacology and Therapeutics (Birdwell et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015 doi: 10.1002/cpt.113)

Posted in Uncategorized by Rachel Mills
0 March 16, 2015

An article reviewing many web-based pharmacogenetic resources has been published in the journal Genomics, Proteomics & Bioinformatics (Zhang et al, 2015). Many of the resources that are discussed are those that are featured by us at CPPN.

Posted in Update by Sanskar Shrivastava | Tags: ,
0 March 12, 2015

Researchers from Assurex Health, Inc (Altar et al, 2015) have reported on four studies using a multi-gene test for PGx factors affecting antidepressants prescribed for major depressive disorder. As part of their analysis, they compared findings from individuals having single-gene PGx tests to those who underwent the multi-gene test. Findings indicate that the multi-gene panel better categorized subjects regarding outcomes and health-care utilization. These findings suggest that PGx panel testing may have improved clinical utility when compared to single-gene tests.

Posted in Update by Sanskar Shrivastava
0 March 9, 2015

British researchers have conducted a review of European drug labels containing pharmacogenetic information (Ehmann et al, 2015). They identified and classified all pharmacogenetic information contained within these labels and found that most often PGx information is included in labels for drugs used to inhibit tumor growth. They also noted that the number of drug labels containing PGx information is steadily increasing and suggests that legislation should be refined to specify how PGx information in labels can be used to improve drug therapy. Similarly, FDA-approved drug labels were reviewed to better understand what types of PGx information were included in patient-targeted sections of drug labels (Haga et al, 2014). Inconsistencies in included PGx information across labels also suggests that more refined specifications should dictate how labels include information about pharmacogenetics.

Posted in Update by Sanskar Shrivastava | Tags: ,
0 January 21, 2015

President Obama touched on the importance of personalized medicine during his State of the Union address on January 20, 2015. He spoke of the U.S. becoming a leader in the new era of personalized medicine that “delivers the right treatment at the right time.” Further, President Obama announced the launch of a Precision Medicine Initiative to ensure that the U.S. remains a leader in the field of personalized medicine by finding cures for diseases associated with genomic risks and improving health.

Posted in Update by Rachel Mills | Tags: ,
0 January 7, 2015

The American Pharmacists Association reported on research published last spring supporting the use of pharmacogenetics in community pharmacists. In the report, they describe findings from a study published in JAPhA, which found that implementing PGx in a community pharmacy setting is feasible. Key challenges to providing PGx testing include reimbursement and some workflow issues. APA also interviewed some community pharmacists who are currently providing PGx services.

http://www.pharmacist.com/pharmacogenomics-emerging-opportunity-pharmacists

Posted in Update by Rachel Mills | Tags: ,
0 October 22, 2014

This month, Managed Care Magazine published an article about a project that tested the feasibility of community pharmacists playing the leading role in PGX testing. The University of North Carolina, Kerr Drug, and LabCorp were involved in the project. Patients who were prescribed clopidogrel underwent pharmacogenetic testing offered by their pharmacist. Based on results, recommendations for medication changes were sent to the prescribing physician and most physician providers accepted those recommendations. Outcomes from this project show that having community pharmacists provide pharmacogenetic testing is a feasible and successful model.

Feel free to read the news release in its entirety here.

Posted in Update by Rachel Mills